<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0375410</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5127</journal-id>
<journal-id journal-id-type="nlm-ta">J Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Pediatr.</journal-id>
<journal-title-group>
<journal-title>The Journal of pediatrics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3476</issn>
<issn pub-type="epub">1097-6833</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26787381</article-id>
<article-id pub-id-type="pmc">4769976</article-id>
<article-id pub-id-type="doi">10.1016/j.jpeds.2015.11.079</article-id>
<article-id pub-id-type="manuscript">NIHMS743470</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A prospective natural history study of Mucopolysaccharidosis Type IIIA</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shapiro</surname>
<given-names>Elsa G.</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nestrasil</surname>
<given-names>Igor</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Delaney</surname>
<given-names>Kathleen A.</given-names>
</name>
<degrees>B.A.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rudser</surname>
<given-names>Kyle</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kovac</surname>
<given-names>Victor</given-names>
</name>
<degrees>B.A.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nair</surname>
<given-names>Nitin</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Richard</surname>
<given-names>Charles W.</given-names>
<suffix>III</suffix>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haslett</surname>
<given-names>Patrick</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Whitley</surname>
<given-names>Chester B.</given-names>
</name>
<degrees>Ph.D., M.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label> University of Minnesota, Department of Pediatrics, Minneapolis, MN, USA</aff>
<aff id="A2"><label>2</label> University of Minnesota, Division of Biostatistics, Minneapolis, MN, USA</aff>
<aff id="A3"><label>3</label> Shire, Lexington MA</aff>
<author-notes>
<fn id="FN1">
<label>a</label>
<p id="P1">formerly at Shire; now at Vertex Pharmaceuticals</p>
</fn>
<fn id="FN2">
<label>b</label>
<p id="P2">formerly at Shire; now at uniQure</p>
</fn>
<fn id="FN3">
<label>c</label>
<p id="P3">formerly at Shire; now at Alnylam Pharmaceuticals, Inc</p>
</fn>
<corresp id="CR1">Corresponding author: Elsa G. Shapiro, Ph.D., 717 Delaware St. SE, Minneapolis, MN 55414, 612-600-8345, <email>shapi004@umn.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>15</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>170</volume>
<fpage>278</fpage>
<lpage>287.e4</lpage>
<!--elocation-id from pubmed: 10.1016/j.jpeds.2015.11.079-->
<abstract>
<sec id="S1">
<title>Objectives</title>
<p id="P4">To characterize the clinical course of mucopolysaccharidosis type IIIA (MPS IIIA), and identified potential endpoints for future treatment trials.</p>
</sec>
<sec id="S2">
<title>Study design</title>
<p id="P5">Children with a confirmed diagnosis of MPS IIIA, functioning above a developmental age of 1 year, were followed for up to 2 years. Cognitive status and brain atrophy were assessed by standardized tests and volumetric MRI, respectively. Liver and spleen volumes, CSF and urine biomarker levels were measured.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P6">Twenty-five children, from 1.1 to 18.4 years old, were enrolled, and 24 followed for at least 12 months. 19 exhibited a rapidly progressing form of MPS IIIA (RP), and 5, a more slowly progressing form (SP). Children with RP plateaued in development by 30 months, followed by rapid regression after 40 to 50 months. Cognitive developmental quotients (DQ) in patients with RP showed consistent steep declines associated with progressive cortical gray matter atrophy. Children with SP had a similar but more prolonged course. Liver and spleen volumes were approximately double normal size, and CSF and urine HS levels were elevated and relatively constant over time.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P7">DQ and cortical gray matter volumes are sensitive markers of disease progression in MPS IIIA, and may have utility as clinical endpoints in treatment trials. For optimal outcomes, treatment may need to be instituted in children before the onset of steep cognitive decline and brain atrophy.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>